Overview
Severe early-childhood-onset retinal dystrophy (sometimes called SECORD) is a group of inherited eye conditions that cause serious vision problems starting in the first few years of life. It is closely related to a condition called Leber congenital amaurosis (LCA) but is distinguished by its onset in early childhood rather than at birth. The disease affects the retina, which is the light-sensitive layer at the back of the eye responsible for converting light into signals the brain can understand. When the retina does not work properly, children experience significant vision loss that can progress over time. Key symptoms include poor vision in dim light (night blindness), reduced central and side vision, involuntary eye movements (nystagmus), and sensitivity to bright light. Children may also have sluggish or absent pupil reactions to light. Over time, the retina can show visible signs of damage, such as thinning or pigment deposits, which an eye doctor can see during an exam. The treatment landscape has changed dramatically in recent years. For patients with mutations in the RPE65 gene specifically, an FDA-approved gene therapy called voretigene neparvovec-rzyl (Luxturna) is available. This treatment delivers a working copy of the RPE65 gene directly into the retina and can meaningfully improve vision. For patients with mutations in other genes, treatment remains largely supportive, including low-vision aids, orientation and mobility training, and ongoing monitoring. Research into additional gene therapies and other approaches is actively underway for many of the other genetic causes.
Also known as:
Key symptoms:
Severe vision loss starting in early childhoodDifficulty seeing in dim light or at night (night blindness)Involuntary back-and-forth eye movements (nystagmus)Sensitivity to bright light (photophobia)Sluggish or absent pupil response to lightLoss of side (peripheral) visionLoss of central vision over timeEye poking or pressing (a habit some children develop)Difficulty tracking objects or making eye contactFarsightedness or other refractive errorsThinning of the retina visible on eye examsPigment deposits in the retinaReduced or absent signals on electroretinography (ERG) testing
Clinical phenotype terms (33)— hover any for plain English
Variable
Can be inherited in different ways depending on the underlying gene
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Severe early-childhood-onset retinal dystrophy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Severe early-childhood-onset retinal dystrophy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Severe early-childhood-onset retinal dystrophy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Severe early-childhood-onset retinal dystrophy.
Community
No community posts yet. Be the first to share your experience with Severe early-childhood-onset retinal dystrophy.
Start the conversation →Latest news about Severe early-childhood-onset retinal dystrophy
No recent news articles for Severe early-childhood-onset retinal dystrophy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific gene is causing my child's retinal dystrophy, and does it qualify for gene therapy like Luxturna?,How quickly is my child's vision expected to change over the coming years?,Are there any clinical trials my child might be eligible for?,Should my child be screened for any other health problems related to this genetic condition, such as kidney issues?,What low-vision aids and educational supports should we put in place now?,How often should my child have eye exams and ERG testing to monitor progression?,What is the chance that our other children or future children could have this condition, and should family members be tested?
Common questions about Severe early-childhood-onset retinal dystrophy
What is Severe early-childhood-onset retinal dystrophy?
Severe early-childhood-onset retinal dystrophy (sometimes called SECORD) is a group of inherited eye conditions that cause serious vision problems starting in the first few years of life. It is closely related to a condition called Leber congenital amaurosis (LCA) but is distinguished by its onset in early childhood rather than at birth. The disease affects the retina, which is the light-sensitive layer at the back of the eye responsible for converting light into signals the brain can understand. When the retina does not work properly, children experience significant vision loss that can progr
At what age does Severe early-childhood-onset retinal dystrophy typically begin?
Typical onset of Severe early-childhood-onset retinal dystrophy is childhood. Age of onset can vary across affected individuals.